Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis

• Published in: Rheumatology (Oxford, England) England), 2022-10, Vol.61 (10), p.4130-4135
• Main Authors: Tsuji, Hideaki, Kuramoto, Nobuo, Sasai, Tsuneo, Shirakashi, Mirei, Onizawa, Hideo, Kitagori, Koji , Akizuki, Shuji, Nakashima, Ran, Watanabe, Ryu, Onishi, Akira, Murakami, Kosaku, Yoshifuji, Hajime, Tanaka, Masao, Hashimoto, Motomu, Ohmura, Koichiro, Morinobu, Akio
• Format: Article
• Language: English
• ISSN: 1462-0324; 1462-0332
• DOI: 10.1093/rheumatology/keac047

Abstract Objective The aim of this study was to investigate association of autoantibodies with scleroderma renal crisis (SRC) among Japanese patients. Methods The clinical characteristics and mortality of 330 patients with sytemic screlosis (SSc) at Kyoto University Hospital were retrospectively analysed, focusing on possible association with anti-topoisomerase I (anti-topo I), anti-centromere (ACA), anti-RNA polymerase III (RNAPIII) and/or anti-U1-RNP. Logistic regression analyses were performed to reveal any association of these autoantibodies with the development and mortality of SRC. Results SRC was observed in 24 out of 330 SSc patients, including patients with anti-topo I (n = 12/24, 50%), anti-RNAPIII (n = 7/24, 29%), anti-U1-RNP (n = 5/24, 21%) and ACA (n = 3/24, 13%). Anti-U1-RNP [odds ratio (95% CI), 3.63 (1.11, 10.2)], anti-topo I [3.22 (1.37, 7.57)] and anti-RNAPIII (3.29 [1.16, 8.70]) were associated with the development of SRC. Furthermore, anti-topo I [6.00 (1.11, 41.1)] was associated with 1-year mortality of SRC. The 1-year survival rate after the onset of SRC among all patients and among those positive for anti-topo I was 54% and 33%, respectively. In contrast, the survival rate in patients negative for anti-topo I was 75%, of which the survival rate of patients positive for anti-RNAPIII and ACA was 83% and 100%, respectively. Conclusion Specific SSc-related autoantibodies were associated with the morbidity and mortality of SRC.